Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice

Carcinogenesis

Volumn 18, Issue 5, 1997, Pages 1001-1006

  Duperron, Caroline ^a   Castonguay, Andre ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; ACETYLSALICYLIC ACID; CYTOCHROME P450; ENZYME INHIBITOR; NITROSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROADIFEN; SALICYLIC ACID DERIVATIVE; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER PREVENTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG METABOLISM; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADENOMA; ANIMALS; ASPIRIN; CELLS, CULTURED; CYTOCHROME P-450 CYP1A2; ENZYME ACTIVATION; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED A; NITROSAMINES; PRODRUGS; SULINDAC;

EID: 0031416517     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.5.1001     Document Type: Article

References (43)

1. Goodman Gilman, A., Goodman, L.S. and Gilman, A. (1990) Analgesic-antipyretics, anti-inflammatory agents: the salicylates. In Goodman, L.S. and Gilman, A. (eds) The Pharmacological Basis of Therapeutics, 8th edn. MacMillan Publishing Co., New York, pp. 644-654.
2. Trujillo, M.A., Garewald, H.S. and Sampliner, R.E. (1994) Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer: at what cost? Dig. Dis. Sci., 39, 2260-2266.
3. Schreinemachers, D.M. and Everson, R.B. (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5, 138-146.
4. Thun, M.J., Namboodiri, M.M., Calle, E.E., Flanders, W.D. and Heath, C.W. Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res., 53, 1322-1327.
5. Brogden, R.N., Heel, R.C., Speight, T.M. and Avery, G.S. (1978) Sulindac: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs, 16, 97-114.
6. Duggan, D.E. (1981) Sulindac: therapeutic implications of the prodrug/ pharmacophore equilibrium. Drug Metab. Rev., 12, 325-337.
7. Strong, H.A., Warner, N.J., Renwick, A.G. and George, C.F. (1985) Sulindac metabolism: The importance of an intact colon. Clin. Pharmacol. Ther., 38, 387-393.
8. Van Arman, C.G., Risley, E.A., Nuss, G.W., Hucker, H.B. and Duggan, D.E. (1976) Pharmacology of sulindac. In Huskisson, E.C. and Franchimont, P. (eds) Clinoril in the Treatment of Rheumatic Disorders: A New Nonsteroidal Antiinflammatory/Analgesic Agent. Proceedings of a Symposium VIII European Rheumatology Congress, Helsinski 1-7 June 1975. Raven Press, New York, p. 9.
9. Waddell, W.R. and Loughry, R.W. (1983) Sulindac for polyposis of the colon. J. Surg. Oncol., 24, 83-87.
10. Reddy, B.S., Maruyama, H. and Kelloff, G. (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47, 5340-5346.
11. Rubio, C.A. (1984) Antitumoral activity of indomethacin on experimental esophageal tumors. J. Natl Cancer Inst., 72, 705-707.
12. Takahashi, M., Furukawa, F., Toyoda, K., Sato, H., Hasegawa, R., Imaida, K. and Hayashi, Y. (1990) Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis, 11, 393-395.
13. Tanaka, T., Nishikawa, A., Mori, Y., Morishita, Y. and Mori, H. (1989) Inhibitory effects of nonsteroidal antiinflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Lett., 48, 177-182.
14. Carte, C.A., Milholland, R.J., Shea, W. and Ip, M.M. (1983) Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res., 43, 3559-3562.
15. Rao, A.R. and Hussain, S.P. (1988) Modulation of methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse by indomethacin. Cancer Lett., 43, 15-19.
16. Rao, C.V., Rivenson, A., Simi, B., Zang, E., Kelloff, V.S. and Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent. Cancer Res., 55, 1464-1472.
17. Reddy, B.S., Rao, C.V, Rivenson, A. and Kelloff, G. (1993) Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14, 1493-1497.
18. Sakata, T., Hasegawa, R., Johansson, S.L., Zenser, T.V. and Cohen, S.M. (1986) Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res., 46, 3903-3906.
19. Pepin, P., Bouchard, L., Nicole, P. and Castonguay, A. (1992) Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis, 13, 341-348.
20. Jalbert, G. and Castonguay, A. (1992) Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett., 66, 21-28.
21. US Department of Health and Human Services (1989) Reducing the health consequences of smoking, 25 years of progress. Office on Smoking and Health. DHHS Publication No. CDC-89-8411, pp. 79-101.
22. Adams, J.D., Lee, S.J., Vinchkoski, N., Castonguay, A. and Hoffmann, D. (1983) On the formation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone during smoking. Cancer Lett., 17, 339-346.
23. Fischer, S., Spiegelhalder, B., Eisenbarth, J. and Preussmann, R. (1990) Investigations on the origin of tobacco-specific nitrosamines in mainstream smoke of cigarettes. Carcinogenesis, 11, 723-730.
24. Fischer, S., Castonguay, A., Kaiserman, M., Spiegelhalder, B. and Preussmann, R. (1990) Tobacco-specific nitrosamines in Canadian cigarettes. J. Cancer Res. Clin. Oncol., 116, 563-568.
25. Hecht, S.S. and Hoffmann, D. (1989) The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surv., 8, 273-294.
26. Hecht, S.S. and Hoffmann, D. (1988) Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis, 9, 875-884.
27. Belinsky, S.A., Stefanski, S.A. and Anderson, M.W. (1993) The A/J mouse lung as a model for developing new chemointervention strategies. Cancer Res., 53, 410-416.
28. Gonzalez, F.J., Crespi, C.L. and Gelboin, H.V. (1991) cDNA-expressed human cytochrome P-450s: a new age of molecular toxicology and human risk assessment. Mutat. Res., 247, 113-127.
29. Yamazaki, H., Inui, Y., Yun, C.H., Guengerich, F.P. and Shimada, T. (1992) Cytochrome P-450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13, 1789-1794.
30. Smith, T.J., Guo, Z., Gonzalez, F.J., Guengerich, F.P., Stoner, G.D. and Yang, C.S. (1992) Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res., 52, 1757-1763.
31. Penman, B.W., Reece, J., Smith, T., Yang, C.S., Gelboin, H.V., Gonzalez, F.J. and Crespi, C.L. (1993) Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics, 3, 28-39.
32. Smith, T.J., Stoner, G.D. and Yang, C.S. (1995) Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P-450, lipoxygenase, and hydroperoxides. Cancer Res., 55, 5566-5573.
33. Smith, T.J., Guo, Z.Y, Guengerich, F.P. and Yang, C.S. (1995) Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P-450 1A2 and inhibition by phenethyl isothiocyanate (PEITC). Proc. Am. Assoc. Cancer Res., 36, 153.
34. Jorquera, R., Castonguay, A. and Schuller, H.M. (1992) Effects of pregnancy and ethanol treatment on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by hamster liver and lung microsomes. Drug Metab. Dispos., 20, 510-517.
35. Shimkin, M.B. and Stoner, G.D. (1975) Lung tumors in mice: application to carcinogenesis bioassay. Adv. Cancer Res., 21, 1-58.
36. National Cancer Institute of Canada (1992) Canadian Cancer Statistics 1992. Toronto, Canada, p. 14.
37. Fu, C.J., Melethil, S. and Mason, W.D. (1991) The pharmacokinetics of aspirin in rats and the effect of buffer. J. Pharmacokin. Biopharm., 19, 157-173.
38. Smith, T.J., Guo, Z., Hong, J.Y. Ning, S.M., Thomas, P.E. and Yang, C.S. (1992) Kinetics and enzyme involvement in the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in microsomes of rat lung and nasal mucosa. Carcinogenesis, 13, 1409-1414.
39. GUO, Z., Smith, T.J., Thomas, P.E. and Yang, C.S. (1992) Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by inducible and constitutive cytochrome P-450 enzymes in rats. Arch. Biochem. Biophys., 298, 279-286.
40. Marnett, L.J. (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52, 5575-5589.
41. Bilodeau, J.F., Wang, M., Chung, F.L. and Castonguay, A. (1995) Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice. Free Rad. Biol. Med., 18, 47-54.
42. Thiessen, J.J. (1982) Pharmacokinetics of salicylates. In Barnett, H.J.M., Hirsh, J. and Mustard, J.F. (eds) Acetylsalicylic Acid: New Uses for an Old Drug. Raven Press, New York, pp. 49-61.
43. Bouchard, L. and Castonguay, A. (1993) Inhibitory effects of nonsteroidal antiinflammatory drugs (NSAIDs) on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in mouse lung explants. Drug Metab. Disp., 21, 293-298.